Debate Heats Up on Impella CP Use in Cardiogenic Shock: THT 2025 Panel Discussion
BOSTON, MA — At THT 2025, medical professionals delved into the implications of the recently published DanGer Shock trial, examining whether the Impella CP microaxial flow pump should be strongly recommended for use in patients with STEMIs complicated by cardiogenic shock.
Key Findings of the DanGer Shock Trial
The trial, presented at the American College of Cardiology (ACC) 2024 Scientific Session and published in the New England Journal of Medicine, demonstrated that routine use of the Impella CP microaxial flow pump lowered 6-month mortality rates in patients with STEMI complicated by cardiogenic shock compared to standard care. Specifically, it showed a 12.7% absolute difference in favor of Impella CP, with a number needed to treat (NNT) of 8.
Strong Class I vs. Reasonable Class IIa Recommendation
During the THT debate, experts argued about the strength of future recommendations for the Impella CP. Two key figures, Manreet Kanwar, MD from the University of Chicago, IL, and Navin Kapur, MD from Tufts University School of Medicine, presented contrasting viewpoints.
Arguments Against a Strong Recommendation
Kanwar advocated for a weaker Class IIa recommendation, citing several concerns. The DanGer Shock trial took over a decade to complete, and results varied by country. In Denmark, where the trial began, the improvement was statistically significant, but in Germany and the UK, the difference was less pronounced.
Kanwar also pointed out potential issues with the trial’s generalizability. Women were underrepresented, and the device did not provide the same benefit in that subgroup. Additionally, only a third of STEMI patients with shock today meet the trial’s inclusion criteria. Moreover, she noted that a significant proportion of control patients were stabilized and discharged from ICU within 72 hours, suggesting that better management may have contributed to improved outcomes.
Arguments in Favor of a Strong Recommendation
Kapur, recently hired as the global chief medical and scientific officer at Johnson & Johnson MedTech, which acquired Abiomed, argued for a Class I recommendation. He emphasized the compelling survival benefit observed in DanGer Shock. Kapur stated that the absolute difference through six months is significant and can’t be ignored, adding that the NNT for survival, especially in younger patients, was just 5.
He also compared the DanGer Shock trial to previous studies like SHOCK and CULPRIT-SHOCK, noting that DanGer Shock is the only MCS trial to show a positive primary endpoint. Kapur highlighted the trial’s high-quality evidence from an RCT, supported by a meta-analysis and several registry studies.
The Role of Protocols in Community Use
The panel discussion further addressed practical concerns about implementing Impella CP in community hospitals. Joyce Wald, DO from the Hospital of the University of Pennsylvania, suggested that stronger recommendations could drive more early use of the device, emphasizing the need for robust post-deployment protocols and escalation strategies.
Ajay Kirtane, MD from NewYork-Presbyterian/Columbia University Irving Medical Center, highlighted the importance of proper protocols to ensure that revascularization and post-revascularization care are high-quality. He echoed Kapur’s call for significant educational initiatives to support cardiogenic shock management in the community.
Challenges in Implementation
David Cohen, MD from St. Francis Hospital & Heart Center, pointed out the challenges of managing these patients in smaller, less equipped community hospitals. He advocated for the establishment and testing of transfer protocols to ensure patients receive adequate care post-deployment. Cohen likened these concerns to the pushback faced in bringing STEMI care into community hospitals.
Kapur agreed, referencing the Cardiovascular Patient Outcomes Research Team (CPORT) initiative, which showed that with appropriate support and educational efforts, successful outcomes can be achieved in community settings.
Toward Standardized Care
Alexandra Lansky, MD from the Yale School of Medicine, suggested that the DanGer Shock results represent a starting point for implementing Impella CP in broader practice. She drew a parallel to the introduction of door-to-balloon times for PCI, noting that it took time to ensure that most patients received treatment within the recommended window.
Lansky emphasized that the trial sets high standards for treatment, and with proper education and protocols, hospitals can deliver the quality of care seen in national centers.
Conclusion
The debate at THT 2025 centers around balancing the promising results of the DanGer Shock trial with the practical realities of widespread implementation. While the survival benefits of Impella CP are compelling, experts emphasize the need for robust educational programs and clear protocols to ensure high-quality care in community settings.
As guidelines are updated, it remains to be seen how strongly the medical community will recommend the use of Impella CP. However, one thing is certain: the next steps will involve both innovation and stringent monitoring to achieve better outcomes for patients with cardiogenic shock.
Join the conversation and share your thoughts! Do you think a strong recommendation for Impella CP is warranted? Leave your comments below, and don’t forget to subscribe to Archynetys for more updates from the medical community.
